In this expert Q&A, Margaret A. Lampe, RN, MsC, discusses the elimination of perinatal HIV transmission, elimination goals set out by the CDC, next steps for research, and more.
In this interview, Jessica Rodrigues, MS, answers questions about barriers to the access of pre-exposure prophylaxis (PrEP), funding, stigma, and choices of PrEP. She also spoke about these topics during...
PrEP has become more mainstream in the media, and the USPSTF recently recommended PrEP for all at-risk populations. Richard Chaisson, MD, shines light on these at-risk populations.
New research indicates that many women living with HIV may prefer a monthly long-acting injectable antiretroviral therapy, once FDA-approved, instead of daily pills. Consultant360 discussed these findings...
Consultant360 spoke with Keith Horvath, PhD, about his study, which indicated that technology-assisted HIV testing interventions could serve as a key strategy in reaching national and global targets for HIV...
A new economic modeling study published in The Lancet HIV has shed light on interventions needed to reach national targets for the Ending the HIV Epidemic initiative. Infectious Diseases Consultant...
Infectious Diseases Consultant spoke with Tingting Zhang, PhD, whose new study indicated that failure to initiate antiretroviral therapy (ART) within 18 months of discontinuation is common among Medicaid...
Kaku So-Armah, PhD, answered our questions about his recent review, in which he and his colleagues discussed traditional and non-traditional risk factors for cardiovascular disease in the context of HIV,...
Infectious Diseases Consultant spoke with Helen Kelly, PhD, about her recent study, which suggested that early initiation and effective use of ART at high nadir CD4 counts may be associated with decreased...
Infectious Diseases Consultant spoke with Paul K. Drain, MD, an associate professor at the University of Washington, whose new study indicated that point-of-care viral load testing can both simplify...
